

# Antibiotics & other antibacterial chemotherapeutics of various structures

# Chloramphenicol group (“amphenicols”)

$R^1 = -NO_2$

$R^2 = -CHCl_2$

**chloramphenicol**

- isolated from *Streptomyces venezuelae* in 1947, now prepared synthetically
- spectrum: both G<sup>+</sup> and G<sup>-</sup>, e.g. *Salmonella*, *Rickettsia*, *Bordetella pertussis*, *Neisseria*, *Haemophilus*, *Klebsiela*, *Enterobacter*, *Staphylococcus aureus*, *Streptococcus* ...
- mode of action: proteosynthesis inhibition: blocks peptidyltransferase
- **adverse effect: irreversible aplastic anaemia** ⇒ **systemic use strongly limited**  
*Chloramphenicolum PhEur*

Ophthalmic-chloramphenicol Léčiva® ung., Spersadex® gtt. opht.  
(+dexamethason)

$R^1 = -NO_2$

$R^2 = -CH_2N_3$

**azidamphenicol**


Ophthalmic-azaphenicol® oph. gtt.

$R^1 = CH_3SO_2 -$

$R^2 = -CHCl_2$


**thiamphenicol**

*Thiamphenicolum PhEur*




## Stereochemistry and activity of chloramphenicol



1R, 2R  
D-(*-*)-threo  
active  
rel. activity 100



1S, 2S  
L-(+)-threo  
rel. activity < 0,4  
also dextromycin




1R, 2S  
D-(+)-erythro  
rel. activity < 0,4





1S, 2R  
L-(*-*)-erythro  
rel. activity 1-2

## Structure-activity relationships (SAR) in amphenicols

- structural fragment necessary for the activity: (1R, 2R)-2-amino-1-phenyl-1,3-propanediol
- $R^1 = -NO_2$ , but also  $-SCH_3$  or  $-SO_2CH_3$  (almost the same activity as in chloramphenicol)
- the amide side chain must contain N-H;  $R^2$  has an impact to the activity in accordance with its bulkiness and electronegativity ( $R^2=OCCHBr_2$  retains 80 % of activity of chloramphenicol)
- esterification of primary -OH  $\Rightarrow$  loss or significant  $\downarrow$  of activity *in vitro*; esters are, however, rapidly hydrolysed ( $\Rightarrow$  ester prodrugs)
- absolute configuration is of fundamental importance for the activity; only 1R, 2R (= D-*threo*) is highly active, 1S, 2R (= L-*erythro*) retains minimal activity, while 1S, 2S (= L-*threo*) and 1R, 2S (=D-*erythro*) are nearly inactive  $\Rightarrow$  the activity depends more on the configuration on C1




## Chloramphenicol prodrugs optimized for particular ways of administration




R<sup>2</sup>  
H

chloramphenicol sodium succinate  
*Chloramphenicoli natrii succinatis*  
*PhEur*  
Chloramphenicol® ICN plv. inj. sol.

or




H



chloramphenicol palmitate  
*Chloramphenicoli palmitatis* PhEur  
●nearly insoluble in water, bitter taste suppressed


## Lincosamides



<b>R<sup>1</sup></b>	<b>R<sup>2</sup></b>	<b>R<sup>3</sup></b>	<b>R<sup>4</sup></b>	<b>R<sup>5</sup></b>	<b>R<sup>6</sup></b>	
C <sub>3</sub> H <sub>7</sub>	CH <sub>3</sub>	OH	H	H	H	<b>lincomycin</b> isolated from <i>Streptomyces lincolnensis</i> var. <i>lincolnensis</i> <i>Lincomycini hydrochloridum monohydricum PhEur</i> Lincocin® inj. sol., Lekomycin P® a.u.v. plv. sol., Neloren® cps. (base)
C <sub>2</sub> H <sub>5</sub>	CH <sub>3</sub>	OH	H	H	H	<b>lincomycin B</b> (up to 5 % in pharmacopoeial lincomycin)
C <sub>3</sub> H <sub>7</sub>	CH <sub>3</sub>	H	Cl	H	H	<b>clindamycin</b> <i>Clindamycini hydrochloridum PhEur</i>
C <sub>3</sub> H <sub>7</sub>	CH <sub>3</sub>	H	Cl	H	OPO(OH) <sub>2</sub>	<b>Clindamycin dihydrogen phosphate</b> <i>Clindamycini dihydrogenphosphas</i> Dalacin C®
C <sub>2</sub> H <sub>5</sub>	CH <sub>3</sub>	H	Cl	H	H	<b>clindamycin B</b> (max. 2 % in pharmacopoeial clindamycin)

- mode of action: protheosynthesis inhibition by inhibition of peptide bond formation by peptidyl transferase
- bacteriostatic
- spectrum: narrow; G<sup>+</sup> and anaerobs, *Staphylococcus*, *Streptococcus*, *Clostridium*, *Bacteroides* ...

# Spectinomycin




(2R,4aR,5aR,6S,7S,8R,9S,9aR,10aS)-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)decahydro-4H-pyran[2,3-b][1,4]benzodioxine-4-on

## spectinomycin

- an antibiotic produced by *Streptomyces spectabilis*
- mode of action: protheosynthesis inhibition; in particular movement between mRNA and a ribosome
- bactericidal
- spectrum: *Neisseria gonorrhoeae*, *Staphylococcus*, *Streptococcus*, *Enterococcus*, *E. coli*, *Haemophilus*, *Proteus*, *Bacteroides*  
formerly the only antibiotic for treatment of gonorrhoea  
Spectam scour halt® a.u.v. gel, Mucospectom® a.u.v. (+linkomycin.HCl)


# Glycopeptides



## vancomycin

- isolated from *Streptomyces orientalis*  
Edicin® inj. plv. sol., Vancocin CP® inj. sic.


- mode of action: inhibition of bacterial cell wall building
- the resistance to them need not be crossed
- bactericidal
- parenteral administration only
- spectrum: narrow; G<sup>+</sup>: *Staphylococcus*, *Streptococcus*, *Enterococcus*, *Clostridium* ...



## teicoplanin


- isolated from *Actinoplanes teichomyceticus*  
Targocid® inj. sic.

# Glycopeptides



**ristocetin A**

- a mixture isolated from *Nocardia lurida*
- toxic, agglutination of platelets, blood clotting




**ristocetin B**

## Ansamycins

- contain an aromatic ring non-adjoining positions of which are linked with a macrocyclic lactame ring


## Rifamycins

- based on naphthalene ring
- mode of action: inhibition of RNA synthesis by blocking of DNA-dependent RNA-polymerase by forming a stable complex with the enzyme
- bacteriostatic, bactericidal in higher doses




R<sup>1</sup>

-H



R<sup>2</sup>

-H




**rifamycin B**


• natural antibiotic produced by *Amycolatopsis mediterranei*

**rifamycin SV**

*Rifamycinum natricum PhEur*



**rifamide**




**rifampicin** (syn. rifampin [USAN])

*Rifampicinum PhEur*

• *Mycobacterium tuberculosis*, *M. leprae* and other both G<sup>+</sup> and G<sup>-</sup>

Arfincin® cps., Benemycin® cps.

## Rifamycins




**rifabutin**

*Rifabutinum PhEur*

- semi-synthetic
- *M. avium-intracellulare*
- Mycobutin ® cps.


## Rifamycins



### rifaximin

- non-absorbable antibiotic for treatment of infectious diarrhoea
- Normix® tbl.

## Oxazolidin-2-one derivatives



- fully synthetic antibacterial chemotherapeutic
  - mode of action: inhibits bacterial protein synthesis by binding to 23S rRNA of 50S subunit of ribozome and avoids formation of the functional 70S initiation complex which is a necessary part of the translation process
  - spectrum: G<sup>+</sup> only: aerobs: *Enterococcus*, *Staphylococcus aureus*, *Streptococcus*; anaerobs: *Clostridium perfringens*, *Peptostreptococcus*
  - nosocomial (hospital) and community pneumonias, complicated skin and soft tissues infections
  - adverse effects: MAO inhibition
- Zyvoxid ® por tbl, inf sol